In the run-up to Rare Disease Day 2021 (28 February), Congenica compiled thoughts, news and opinions on the importance of rare disease diagnostics available on the live blog here.
It includes, podcasts, articles and a range of videos with:
- Lynsey Chediak, Project Lead at World Economic Forum discussing what rare disease and precision medicine means to her.
- Jeff D'Angelo, founder of the CHAMP1 Foundation shares with us his thoughts on Rare Disease Day, the community and his son, JJ.
- Allison Watson, founder and CEO of the Ring20 Research and Support group UK, talks to…
In our recent post, we have produced a clear summary infographic of all the key Covid-19 vaccines in full or early use, globally. We've included peer-review references where available, including efficacies, to help you to get up to speed quickly.
https://onyva-agency.com/2021/02/26/global-covid-19-vaccine-summary-and…
New data reveals Knowledge Intensive (KI) firms in Cambridge continue to outperform national figures
Cambridge, UK. 3 March 2021: Medium term data on the growth of the Cambridge economy, right up to the start of the 2020 Covid lockdown, shows persistently higher annual growth rates than the national economy, particularly amongst knowledge-intensive (KI) firms. This confirms Cambridge’s status as one of the largest concentrations of KI employment in Europe. However, there are also indications that start-ups and non-KI firms are finding conditions in the city less attractive. The authoritative data released today via the Cambridge Cluster Insights dashboard by the Centre…
PHILADELPHIA and OXFORD, March 2, 2021 - WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology and medical device industries, today announced that it has completed the acquisition of OXGENE, a pioneering United Kingdom-based contract research and development organization that designs and develops scalable gene therapy technologies. This acquisition enables WuXi AppTec to offer its customers end-to-end support in the creation and development of cutting-edge cell and gene therapies for patients in need worldwide.
OXGENE…
Cambridge, UK, 02 March 2021: CN Bio, a leading developer of single and multi-organ microphysiological systems (MPS), otherwise known as organ-on-a-chip, today announced it has received a grant from Innovate UK, the UK’s innovation agency, to develop human-relevant MPS to advance investigations into SARS-CoV-2 infection. The funding will be used to develop and test advanced cell culture models that represent different regions of the lung and subsequently linking these models to other organ systems, such as liver and gut, to inform the rapid development of novel therapeutics.
The fast-moving…
Bruntwood SciTech, the UK’s leading property provider dedicated to the growth of the science and technology sector, has acquired a long leasehold over Melbourn Science Park from TTP for £46.2m and will work closely with the local planning authority in the coming months to develop a new ambitious masterplan for the 16.4 acre site; creating a long term vision for the future growth of the science park as a leading science and technology cluster in Cambridge.
The new strategic partnership will see Bruntwood SciTech and TTP, which has many years of experience of working in life sciences,…
SOMERSET, N.J. and GOSSELIES, BELGIUM – February 23, 2021 — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, and Delphi Genetics, a plasmid DNA (pDNA) cell and gene therapy contract development and manufacturing organization (CDMO) based in Gosselies, Belgium, today announced that they have entered into a final and definitive agreement whereby Catalent will acquire 100% of the shares of Delphi Genetics. Catalent is also announcing the launch of pDNA…
PLG is very excited to announce the re-start of our monthly newsletter, to keep everyone up to date with our activities and news.
Please see link:
https://productlifegroup.com/blog/february-newsletter/
Cambridge, UK, 23rd February 2021: Chesterford Research Park is delighted to confirm the expansion of Camena Bioscience within the Science Village Building at the Park. The developer of an industry-leading DNA synthesis technology has renewed its existing lease for a further five years and in tandem taken an additional 1,993 sq ft adjoining suite on the same terms.Founded in 2016, Camena Bioscience has been based at Chesterford Research Park since its incorporation. The company’s multi-enzymatic technology, called gSynth™, has dramatically improved the accuracy of DNA synthesis…